open access

Vol 78, No 3 (2010)
ORIGINAL PAPERS
Published online: 2010-05-11
Submitted: 2013-02-22
Get Citation

Hepatocyte growth factor in exhaled breath and BAL fluid in sarcoidosis

Wojciech J. Piotrowski, Zofia Kurmanowska, Adam Antczak, Jerzy Marczak, Paweł Górski
Pneumonol Alergol Pol 2010;78(3):187-191.

open access

Vol 78, No 3 (2010)
ORIGINAL PAPERS
Published online: 2010-05-11
Submitted: 2013-02-22

Abstract


Introduction: Hepatocyte growth factor (HGF) is a strong mitogen stimulating lung epithelial cell growth. Elevated levels of HGF have been reported in various biological materials of patients with acute respiratory distress syndrome and in patients recovering from pneumonia or pneumonectomy. Sarcoidosis may be complicated by lung fibrosis. Consequently, HGF could be considered a new biomarker identifying patients with a higher risk of lung fibrosis. The aim of the study was to verify whether: 1. HGF is measurable in bronchoalveolar lavage fluid (BALF) and exhaled breath condensate (EBC); 2. HGF in BALF or EBC is impaired in sarcoidosis; and 3. HGF correlates with chosen activity and prognostic markers.
Material and methods: Sixty-four EBC and 30 BALF of sarcoid patients, and 15 and 9 of healthy controls, respectively, were collected for the measurement of HGF using an ELISA test.
Results: HGF was detectable in 62% of EBC samples (56% sarcoidosis and 87% of controls) and in all the BALF samples. EBC and BALF concentrations were not different in comparison to the controls. Moreover, no correlation was found between EBC/BALF concentrations and radiological stage, lung function tests, duration of disease, number of relapses, BALF lymphocytes, serum ACE, or serum and urine calcium concentrations.
Conclusions: HGF is detectable in BAL and EBC. However, it does not distinguish sarcoidosis patients from healthy subjects. The above, as well as the lack of correlations with various parameters of disease activity and severity rule out EBC/ /BALF HGF as a biomarker for sarcoidosis monitoring.

Abstract


Introduction: Hepatocyte growth factor (HGF) is a strong mitogen stimulating lung epithelial cell growth. Elevated levels of HGF have been reported in various biological materials of patients with acute respiratory distress syndrome and in patients recovering from pneumonia or pneumonectomy. Sarcoidosis may be complicated by lung fibrosis. Consequently, HGF could be considered a new biomarker identifying patients with a higher risk of lung fibrosis. The aim of the study was to verify whether: 1. HGF is measurable in bronchoalveolar lavage fluid (BALF) and exhaled breath condensate (EBC); 2. HGF in BALF or EBC is impaired in sarcoidosis; and 3. HGF correlates with chosen activity and prognostic markers.
Material and methods: Sixty-four EBC and 30 BALF of sarcoid patients, and 15 and 9 of healthy controls, respectively, were collected for the measurement of HGF using an ELISA test.
Results: HGF was detectable in 62% of EBC samples (56% sarcoidosis and 87% of controls) and in all the BALF samples. EBC and BALF concentrations were not different in comparison to the controls. Moreover, no correlation was found between EBC/BALF concentrations and radiological stage, lung function tests, duration of disease, number of relapses, BALF lymphocytes, serum ACE, or serum and urine calcium concentrations.
Conclusions: HGF is detectable in BAL and EBC. However, it does not distinguish sarcoidosis patients from healthy subjects. The above, as well as the lack of correlations with various parameters of disease activity and severity rule out EBC/ /BALF HGF as a biomarker for sarcoidosis monitoring.
Get Citation

Keywords

sarcoidosis; exhaled breath condensate; bronchoalveolar lavage fluid; hepatocyte growth factor

About this article
Title

Hepatocyte growth factor in exhaled breath and BAL fluid in sarcoidosis

Journal

Advances in Respiratory Medicine

Issue

Vol 78, No 3 (2010)

Pages

187-191

Published online

2010-05-11

Bibliographic record

Pneumonol Alergol Pol 2010;78(3):187-191.

Keywords

sarcoidosis
exhaled breath condensate
bronchoalveolar lavage fluid
hepatocyte growth factor

Authors

Wojciech J. Piotrowski
Zofia Kurmanowska
Adam Antczak
Jerzy Marczak
Paweł Górski

References (16)
  1. Krychniak-Soszka A, Kuś J. [Prognostic value of some clinical, radiological, laboratory and functional parameters in sarcoidosis]. Pneumonol Alergol Pol. 2002; 70(11-12): 573–582.
  2. American Thoracic Society. Statement on Sarcoidosis. American Journal of Respiratory and Critical Care Medicine. 1999; 160(2): 736–755.
  3. Yanagita K, Matsumoto K, Sekiguchi K, et al. Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. J Biol Chem. 1993; 268(28): 21212–21217.
  4. Adamson I, Bakowska J. Relationship of Keratinocyte Growth Factor and Hepatocyte Growth Factor Levels in Rat Lung Lavage Fluid to Epithelial Cell Regeneration after Bleomycin. The American Journal of Pathology. 1999; 155(3): 949–954.
  5. Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol. 2002; 282(5): L924–L940.
  6. Verghese GM, McCormick-Shannon K, Mason RJ, et al. Hepatocyte growth factor and keratinocyte growth factor in the pulmonary edema fluid of patients with acute lung injury. Biologic and clinical significance. Am J Respir Crit Care Med. 1998; 158(2): 386–394.
  7. Plantier L, Marchand-Adam S, Marchal-Sommé J, et al. Defect of hepatocyte growth factor production by fibroblasts in human pulmonary emphysema. Am J Physiol Lung Cell Mol Physiol. 2005; 288(4): L641–L647.
  8. Dikmen E, Kara M, Kisa U, et al. Human hepatocyte growth factor levels in patients undergoing thoracic operations. Eur Respir J. 2006; 27(1): 73–76.
  9. Nayeri F, Millinger E, Nilsson I, et al. Exhaled breath condensate and serum levels of hepatocyte growth factor in pneumonia. Respir Med. 2002; 96(2): 115–119.
  10. Faehling M, Anders D, Hetzel M, et al. HGF and IL-6 in BAL fluid of interstitial lung diseases: effect on human lung fibroblasts. Eur Respir J. 2008; 32(Suppl. 52): 316S.
  11. Inoue T, Okada H, Kobayashi T, et al. Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB J. 2003; 17(2): 268–270.
  12. Yang J, Dai C, Liu Y. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol. 2003; 163(2): 621–632.
  13. Mizuno S, Matsumoto K, Li MY, et al. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J. 2005; 19(6): 580–582.
  14. Okunishi K, Dohi M, Nakagome K, et al. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol. 2005; 175(7): 4745–4753.
  15. Marchand-Adam S, Marchal J, Cohen M, et al. Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003; 168(10): 1156–1161.
  16. Marchand-Adam S, Fabre A, Mailleux AA, et al. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174(1): 58–66.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl